A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeutics.

Development of biotherapeutics is hampered by the inherent risk of immunogenicity, which requires extensive clinical assessment and possible re-engineering efforts for mitigation. The focus in the pre-clinical phase is to determine the likelihood of developing treatment-emergent anti-drug antibodies...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Joanne Lin, Stacey L Lee, Anna M Russell, Rong Fong Huang, Micheal A Batt, Shawn S Chang, Andrea Ferrante, Petra Verdino
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/b3a2ef3195954b0488eb8607de448e39
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!